New demonstration of the predictive power of an in silico clinical trial in oncology
13. November 2023 02:00 ET
|
Novadiscovery
New demonstration of the predictive power of an in silico clinical trial in oncology Quantitative Systems Pharmacology (QSP) model of lung cancer and 5,900 digital patients architected to complete...
Novadiscovery announces Nature Communications paper on modeling the disruption to respiratory clinical trials due to mitigation measures against COVID-19
13. April 2022 06:00 ET
|
Novadiscovery
Novadiscovery announces Nature Communications paper on modeling the disruption to respiratory clinical trials due to mitigation measures against COVID-19 Model uses virtual populations and in silico...
Novadiscovery expands Janssen collaboration by implementing its JINKO® clinical trial simulation platform for the development of lung cancer models
16. Dezember 2021 02:00 ET
|
Novadiscovery
Novadiscovery expands Janssen collaboration by implementing its JINKO® clinical trial simulation platform for the development of lung cancer models Janssen intends to use computational disease models...
Novadiscovery Continues Global Expansion with the Launch of its US Headquarters in Boston, MA
02. November 2021 07:00 ET
|
Novadiscovery
Novadiscovery Continues Global Expansion with the Launch of its US Headquarters in Boston, MA The new office will support continued expansion into the US market, NOVA’s largest customer base, and...
Novadiscovery appoints Grégoire Boutonnet as Chief Operating Officer
22. Juli 2021 07:00 ET
|
Novadiscovery
Novadiscovery appoints Grégoire Boutonnet as Chief Operating Officer Appointment of Grégoire supports NOVA’s continued international expansion Lyon, France – 22 July 2021: Novadiscovery (NOVA), a...
Novadiscovery announces new clinical simulation collaboration with Takeda
26. März 2021 08:00 ET
|
Novadiscovery
Novadiscovery announces new clinical simulation collaboration with Takeda Lyon, France – 26 March, 2021 Novadiscovery (“NOVA”), a leading health tech company offering JINKO, a best-in-class...
Novadiscovery announces new clinical simulation collaboration with Takeda
26. März 2021 03:00 ET
|
Novadiscovery
Novadiscovery announces new clinical simulation collaboration with Takeda Lyon, France – 26 March, 2021 Novadiscovery (“NOVA”), a leading health tech company offering JINKO, a best-in-class...
Novadiscovery raises Series A2 financing from Sanofi to advance JINKO, its best-in-class clinical trial simulation platform
16. Februar 2021 07:00 ET
|
Novadiscovery
Novadiscovery raises Series A2 financing from Sanofi to advance JINKO, its best-in-class clinical trial simulation platform NOVA to develop COVID-19 disease model to support Sanofi’s vaccine and...
Novadiscovery raises Series A2 financing from Sanofi to advance JINKO, its best-in-class clinical trial simulation platform
16. Februar 2021 02:00 ET
|
Novadiscovery
Novadiscovery raises Series A2 financing from Sanofi to advance JINKO, its best-in-class clinical trial simulation platform NOVA to develop COVID-19 disease model to support Sanofi’s vaccine and...
Consortium including ElsaLys Biotech and Novadiscovery awarded €3.35 million by Bpifrance to advance inolimomab in graft-versus-host disease
19. Januar 2021 03:30 ET
|
Novadiscovery
Consortium including ElsaLys Biotech and Novadiscovery awarded €3.35 million by Bpifrance to advance inolimomab in graft-versus-host disease NOVA awarded €2.4 million to leverage Jinkō®, its...